Doorgaan naar inhoud

Oncologie

Behandeling van anemie

Erytropoëse-stimulerende middelen

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (opent nieuw venster)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Bron‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Geïndexeerd‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (opent nieuw venster)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (opent nieuw venster)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Bron‎: Acta Haematol 2007;117(3):162-7.

Geïndexeerd‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (opent nieuw venster)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (opent nieuw venster)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Bron‎: Am J Hematol 2013;88(12):990-6.

Geïndexeerd‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (opent nieuw venster)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (opent nieuw venster)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Bron‎: J Clin Oncol 2011;29(28):3791-7.

Geïndexeerd‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (opent nieuw venster)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (opent nieuw venster)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Bron‎: Cancer 2012;118(3):848-55.

Geïndexeerd‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (opent nieuw venster)

Management of anemia in cancer patients. (opent nieuw venster)

Calabrich A, Katz A.

Bron‎: Future Oncol 2011;7(4):507-17.

Geïndexeerd‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (opent nieuw venster)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (opent nieuw venster)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Bron‎: BJU Int 2011;108(10):1582-7.

Geïndexeerd‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (opent nieuw venster)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (opent nieuw venster)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Bron‎: J Clin Oncol 2010;28(13):2239-45.

Geïndexeerd‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (opent nieuw venster)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (opent nieuw venster)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Bron‎: Br J Cancer 2011;105(9):1267-72.

Geïndexeerd‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (opent nieuw venster)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (opent nieuw venster)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Bron‎: J Intern Med 2017;281(3):284-99.

Geïndexeerd‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (opent nieuw venster)

How I treat cancer-associated anemia. (opent nieuw venster)

Gilreath JA, Rodgers GM

Bron‎: Blood 2020;136(7):801-13.

Geïndexeerd‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (opent nieuw venster)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (opent nieuw venster)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Bron‎: Eur J Haematol. 2023 110(4):354-61.

Geïndexeerd‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (opent nieuw venster)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (opent nieuw venster)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Bron‎: Int J Hematol 2015;102(4):401-12.

Geïndexeerd‎: PubMed 26323997

DOI‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (opent nieuw venster)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (opent nieuw venster)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Bron‎: Cancer 2013;119(1):107-14.

Geïndexeerd‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (opent nieuw venster)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (opent nieuw venster)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Bron‎: J Natl Cancer Inst 2013;105(14):1018-26.

Geïndexeerd‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (opent nieuw venster)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (opent nieuw venster)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Bron‎: Cancer Sci 2013;104(4):481-5.

Geïndexeerd‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (opent nieuw venster)

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (opent nieuw venster)

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

Bron‎: Br J Haematol 2019;184(2):134-60.

Geïndexeerd‎: PubMed 30549002

DOI‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 (opent nieuw venster)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (opent nieuw venster)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Bron‎: Support Care Cancer 2012;20(1):159-65.

Geïndexeerd‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (opent nieuw venster)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (opent nieuw venster)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Bron‎: Leuk Lymphoma. 2019;60(9):2324-7.

Geïndexeerd‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (opent nieuw venster)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (opent nieuw venster)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Bron‎: Oncologist 2010;15(9):935-43.

Geïndexeerd‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (opent nieuw venster)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (opent nieuw venster)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Bron‎: Lung Cancer 2012;76(3):478-85.

Geïndexeerd‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (opent nieuw venster)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (opent nieuw venster)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Bron‎: Eur J Haematol 2016;97(1):33-8.

Geïndexeerd‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (opent nieuw venster)

Intraveneus ijzer

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (opent nieuw venster)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Bron‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Geïndexeerd‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (opent nieuw venster)

Intravenous iron in oncology. (opent nieuw venster)

Auerbach M, Ballard H.

Bron‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Geïndexeerd‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (opent nieuw venster)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (opent nieuw venster)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Bron‎: Int J Colorectal Dis 2016;31(3):543-51.

Geïndexeerd‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (opent nieuw venster)

How I treat cancer-associated anemia. (opent nieuw venster)

Gilreath JA, Rodgers GM

Bron‎: Blood 2020;136(7):801-13.

Geïndexeerd‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (opent nieuw venster)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (opent nieuw venster)

Gilreath JA, Stenehjem DD, Rodgers GM.

Bron‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Geïndexeerd‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (opent nieuw venster)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (opent nieuw venster)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Bron‎: Eur J Haematol. 2023 110(4):354-61.

Geïndexeerd‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (opent nieuw venster)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (opent nieuw venster)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Bron‎: Curr Oncol. 2023 24;30(9):7836-51.

Geïndexeerd‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (opent nieuw venster)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (opent nieuw venster)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Bron‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Geïndexeerd‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (opent nieuw venster)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (opent nieuw venster)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Bron‎: World J Gastroenterol 2014;20(8):1972-85.

Geïndexeerd‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (opent nieuw venster)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (opent nieuw venster)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Bron‎: South Asian J Cancer. 2023 15;12(2):93-9.

Geïndexeerd‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (opent nieuw venster)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (opent nieuw venster)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Bron‎: J Clin Oncol 2008;26(10):1619-25.

Geïndexeerd‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (opent nieuw venster)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (opent nieuw venster)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Bron‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Geïndexeerd‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (opent nieuw venster)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (opent nieuw venster)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Bron‎: Ann Oncol 2013;24(2):475-82.

Geïndexeerd‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (opent nieuw venster)

Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions. (opent nieuw venster)

Van Doren L, Steinheiser M, Boykin K, Taylor KJ, Menendez M, Auerbach M

Bron‎: Am J Hematol 2024;99(7):1338-48.

Geïndexeerd‎: PubMed 38282557

DOI‎: 10.1002/ajh.27220

https://pubmed.ncbi.nlm.nih.gov/38282557/ (opent nieuw venster)

ONCOLOGIE
Behandeling van anemie
Nederlands
Behandeling van anemie
https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Contact met lokale vertegenwoordiger van het ziekenhuiscontactcomité

Een wereldwijde gratis 24 uursservice voor artsen die Jehovah’s Getuigen behandelen.

Contact

Medische informatiepakketten

Enkele onderwerpen: klinische strategieën voor de behandeling van hemorragie en anemie zonder bloedtransfusie, het religieuze en ethische standpunt van Jehovah’s Getuigen aangaande medische behandelingen en de diensten die Getuigen de medische wereld aanbieden door middel van hun wereldwijde netwerk van ziekenhuiscontactcomités.

Bekijk downloads

Video’s

Behandelingsopties en medische en ethische overwegingen voor artsen die Getuigen van Jehovah behandelen.

Video's bekijken